세계의 거대세포바이러스 치료 시장(2023-2030년)
Global Cytomegalovirus Treatment Market 2023-2030
세계의 거대세포바이러스(CMV) 치료제 시장은 예측 기간(2023-2030년)에 5.8%의 CAGR을 나타낼 것으로 예상되며, CMV 망막염 및 선천성 CMV 감염의 유병률 증가와 함께 이러한 질환의 치료 및 진단에 대한 인식을 높이는 노력이 증가하고 있습니다. CMV 치료 시장의 성장을 가속하는 주요 요인으로 작용하고 있습니다. 예를 들어 CDC의 최신 데이터에 따르면 2022년 5월 현재 미국에서 매년 약 150명의 영유아가 CMV 감염을 가지고 태어나고 있으며, 그 중 일부는 장기적인 건강 문제를 겪고 있습니다. 영유아가 CMV에 감염되면 성인의 유사한 감염과 관련된 인터페론 반응이 약화됩니다.
같은 정보원에 따르면 CMV 감염과 CMV 감염 재활성화의 위험은 임신 중에도 보고되고 있으며, 선천성 CMV 감염으로 이어질 수 있다고 합니다. 이러한 질병 부담 증가는 효과적인 치료 옵션에 대한 수요를 창출하고 CMV 치료 시장의 성장을 가속할 것으로 예상됩니다. 신약 개발을 위한 임상시험 연구의 신흥 국가 시장이 세계 시장 성장을 촉진할 것으로 보입니다.
지난 4월, 연구진은 임신 중 CMV 감염이 태아에게 전이될 위험을 추정하는 계산기 외부 링크를 개발했습니다. 이 선천성 CMV 감염은 산모의 CMV 1차 감염 사례의 약 20.0%-40.0%에서 발생합니다. 이 계산기는 개인의 특성에 따라 선천성 CMV 가능성을 예측하는 비침습적 방법을 제공함으로써 의료진이 CMV에 감염된 임산부를 상담하는 데 도움을 줄 수 있습니다. 이러한 개발은 유아의 감염률을 낮출 수 있을 것으로 기대됩니다.
모든 지역 중 아시아태평양은 예측 기간 중 상당한 CAGR로 성장할 것으로 예상됩니다. 이 지역의 성장은 CMV 치료제의 주요 용도 중 하나인 줄기세포 연구에 대한 연방 정부의 자금 지원 확대에 기인합니다. 인도에서는 생명공학부(DBT)가 줄기세포의 기초 생물학, 초기 및 후기 중개 연구, 치료 응용 가능성이 있는 유전자 편집 기술 개발, 다양한 인간 질환의 동물 모델 제작 등의 프로젝트를 지원하고 있습니다. 올해까지 총 8,960만 달러의 자금을 지원했습니다.
Title: Global Cytomegalovirus Treatment Market Size, Share & Trends Analysis Report by Drug Type (Cidofovir, Foscarnet, Valganciclovir, and Ganciclovir), By Application (Stem Cell Transplantation, Organ Transplantation, Congenital CMV Infection, and Other Application), By Distribution Channel (Hospital pharmacies, Retail Pharmacies, and E-commerce), Forecast Period (2023-2030).
The global cytomegalovirus (CMV) treatment market is anticipated to grow at a CAGR of 5.8% during the forecast period (2023-2030). The rising prevalence of CMV retinitis and congenital CMV infection, along with increasing initiatives to create awareness regarding treatments and diagnosis of these conditions is a key factor driving the growth of the CMV treatment market. For instance, as per the updated CDC data, as of May 2022, in the US, around 150 infants are born with CMV infections every year, and a few of them have long-term health issues. CMV infection in infants generates an attenuated interferon response associated with a similar infection in the adult.
As per the same source, CMV infection and the risk of reactivation of CMV infection have been reported during pregnancy and can also lead to congenital CMV infection. Thus, the rising disease burden is anticipated to create the demand for effective treatment options, thereby driving the CMV treatment market growth. The increasing clinical trial studies for the development of new drugs are likely to drive the growth of the global market.
In April 2022, the researchers have developed a calculator external link to estimate the risk that CMV infection will pass to a fetus during pregnancy. This congenital CMV infection occurs in about 20.0% to 40.0% of cases of primary maternal CMV infection. By offering a noninvasive way to predict the chance of congenital CMV based on individual characteristics, the calculator may support healthcare provider to counsel pregnant people with CMV. Such developments are anticipated to lower the infection rate in infants.
The global cytomegalovirus treatment market is segmented on the drug type, application, and distribution channel. Based on the drug type, the market is sub-segmented into Cidofovir, Foscarnet, Valganciclovir, and Ganciclovir. Based on the application, the market is sub-segmented into stem cell transplantation, organ transplantation, congenital CMV infection, and other application. Further, on the basis of distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies, and E-commerce.
The global cytomegalovirus treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the presence of key market players along with high healthcare expenditure. The increasing incidences of cytomegalovirus infections along with increasing awareness among consumers also play a crucial role in the regional market growth. For instance, the article published by the National Institute of Neurological Disorders and Stroke (NINDS) in July 2022 mentioned that CMV infected about 50.0% to 80.0% of adults by the age of 40 and is one of the most congenital infections in the US annually. Similarly, the CMV Canada data published in June 2021, mentioned that one in 200 Canadian infants is infected with CMV during pregnancy. The report also mentioned that 1 in 5 congenital CMV had a permanent disability such as hearing loss or developmental delay. Such an increased incidence of CMV among the North American population to create higher demand for effective treatment thereby is driving the growth of the market.
Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing federal funding for stem cell research, which is one of the core application areas of CMV drugs. In India, the Department of Biotechnology (DBT) has supported projects for basic biology of stem cells; early and late translational research; developing gene editing technology for potential therapeutic applications and creation of animal models for various human diseases. As of 2021, the funds released by the DBT during the last three years and the current year in this area is $89.6 million.
The major companies serving the cytomegalovirus treatment market include: F. Hoffmann-La Roche Ltd, Teva Canada Ltd., Gilead Sciences, Inc., Thermo Fisher Scientific, Inc., and Merck & Co., Inc. among others. The market players are considerably contributing to the market growth by the adoption of various strategies including funding for R&D, and new drug development, to stay competitive in the market. For instance, in September 2022, Takeda announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).